Right ventricular and right atrial function and deformation in patients with subclinical hypothyroidism: A two- and three-dimensional echocardiographic study.

Marijana Tadic, MD, PhD †*
Sanja Ilic, MD §
Assoc. Prof. Vera Celic, MD, PhD †¶

† University Clinical Hospital Center “Dr Dragisa Misovic”
Cardiology Department
Heroja Milana Tepica 1
11000 Belgrade, Serbia

§ University Clinical Hospital Center “Dr Dragisa Misovic”
Department of Endocrinology
Heroja Milana Tepica 1
11000 Belgrade, Serbia

¶ Faculty of Medicine
Doktora Subotica 6
11000 Belgrade, Serbia

Potential conflict of interest: NONE

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Corresponding author:
Marijana Tadic, MD, PhD
University Clinical Hospital Center “Dr Dragisa Misovic”
Heroja Milana Tepica 1
11000 Belgrade, Serbia
e-mail: marijana_tadic@hotmail.com

Running title: Subclinical hypothyroidism and right heart
Abstract

Background: We sought to investigate right ventricular (RV) function and deformation assessed by three-dimensional echocardiography (3DE) and speckle tracking in patients with subclinical hypothyroidism (SHT), and to evaluate the influence of levothyroxine therapy on RV remodeling.

Methods: We included 50 untreated women with SHT and 45 healthy control women matched by age. The levothyroxine therapy was prescribed to all SHT patients who were followed one year after euthyroid status was achieved. All study participants underwent laboratory analyses which included thyroid hormone levels, and complete 2DE and 3DE examination.

Results: 3DE RV end-diastolic volume and ejection fraction were significantly reduced in the SHT patients before therapy in comparison with the healthy controls and treated SHT subjects. RV longitudinal strain, systolic and early diastolic strain rates were significantly decreased, whereas RV late diastolic strain rate was increased, in the SHT patients before therapy when comparing with the controls. 2DE speckle tracking imaging revealed that levothyroxine substitution therapy significantly improved RV systolic mechanics, whereas RV diastolic deformation was not completely recovered. RA function and deformation were significantly impacted by SHT. Replacement levothyroxine treatment improved, but did not completely restore RA mechanics in the SHT patients.

Conclusion: RV and RA function and mechanics are significantly affected by SHT. Levothyroxine therapy and one-year maintenance of euthyroid status improved, but did not completely recover RV and RA function and deformation in the SHT patients which implies that right heart remodeling caused by SHT is not reversible in a one-year period.

Key words: subclinical hypothyroidism, right ventricle, mechanics, three-dimensional echocardiography, levothyroxine therapy
Introduction

The cardiovascular system represents one of the most prominent targets of thyroid hormones which is easily detected in overt hyper- or hypothyroidism /1/. The influence of subclinical thyroid dysfunction on the heart and the cardiovascular system is significantly less studied, and pathophysiological mechanisms of this relationship are still unclear /2/. Studies showed that subclinical hypothyroidism (SHT) is associated with left ventricular remodeling, especially hypertrophy and diastolic dysfunction /3-8/. However, the influence of SHT on the right ventricle (RV), as well as the effect of levothyroxine therapy on RV remodeling, has been investigated in several studies which used only pulsed and tissue Doppler for the estimation of RV function /9-14/. To our knowledge, there is no study which used three-dimensional echocardiography (3DE) and two-dimensional (2DE) speckle tracking imaging for assessment of RV function and mechanics in the SHT patients. Additionally, right atrial (RA) mechanics in the SHT patients have not been evaluated so far.

The aim of our investigation was to determine RV and RA function and deformation in the SHT patients, and to evaluate the effect of substitution levothyroxine therapy on RV and RA remodeling in these patients using 3DE and 2DE speckle tracking imaging.

Methodology

Our study enrolled 50 female patients with untreated subclinical hypothyroidism and 45 age-matched healthy female volunteers. The study was conducted at Endocrinology and Cardiology Department, University Clinical Hospital Center "Dr Dragisa Misovic" in Belgrade, Serbia, between January 2010 and June 2013. The etiology of SHT, in all the patients, was chronic autoimmune thyroiditis which was diagnosed by increased circulating antiperoxidase and/or anti-thyroglobulin autoantibodies and diffuse hypoechogenicity by thyroid ultrasound. The inclusion criteria were age (≤ 50 years) and increased serum TSH
level with normal levels of FT3 and FT4. Subjects with symptoms or signs of cardiovascular
disease (arterial hypertension, myocardial infarction, atrial fibrillation, heart failure,
congenital heart disease, valvular disease), obesity (BMI ≥ 30 kg/m^2), asthma, chronic
obstructive lung disease, neoplastic disease, cirrhosis of the liver, kidney failure, sleeping
disorders, or type 2 diabetes mellitus, as well as professional athletes, were excluded from the
study.

Anthropometric measures (height, weight), and laboratory analyses (level of thyroid
hormones, total cholesterol, LDL and HDL cholesterol, triglycerides) were taken from all the
subjects included in the study. Data about smoking habits, family history of coronary artery
disease, asthma and obstructive pulmonary disease were taken from all study subjects.
Fasting venous blood samples were drawn between 08 and 09 o’clock in the morning. None
of the participants used any medication before their inclusion into the study. Normal ranges
for FT3, FT4, TSH, were 1.5–4.1 pg/ml, 11.5-22.7 pmol/l, 0.4–4 mIU/l, respectively. FT3
level was determined by IMMULITE 1000, a competitive analog based immunoassay; FT4
level was assessed by IMMULITE 2000 enzyme – labeled chemiluminescent competitive
immunoassay; and TSH level was determined by using IMMULITE 2000, third generation
TSH, two–site chemiluminescent immunometric assay. After the baseline assessment, the
patients with SHT were assigned to receive levothyroxine replacement starting with 25 µg/d.
TSH was measured every 8 weeks in order to adjust the dose. Euthyroid state was achieved
with a mean dose of 74 µg/d in 18.2 ± 5.3 weeks. Echocardiographic examination was
performed before starting the treatment, and one year after euthyroid state had been achieved
by levothyroxine treatment. Body mass index and body surface area were calculated for each
patient. The study was approved by the local Ethics Committee, and informed consent was
obtained from all the participants.
Echocardiography

Echocardiographic examination was performed by using a 2.5 MHz transducer with harmonic capability of a Vivid 7 ultrasound machine (GE Healthcare, Horten, Norway).

Standard two-dimensional (2DE) echocardiographic examination

The values of all 2DE parameters were obtained as the average value of three consecutive cardiac cycles. The LV end-systolic and end-diastolic diameters (LVEDD), the left ventricle posterior wall (PWT) and interventricular septum thickness, were determined according to the current recommendations /15/. Relative wall thickness was calculated as (2xPWT)/LVEDD. Left ventricular ejection fraction was estimated by using the biplane method. Left ventricular mass was calculated by using the Devereux formula /16/, and indexed for height powered to 2.7.

Transmitral Doppler inflow and tissue pulsed Doppler were obtained in the apical four chamber view. Pulsed Doppler measurements included the transmitral early diastolic peak flow velocity (E), late diastolic flow velocity (A), their ratio (E/A) /17/.

Right ventricle and atrium

The right ventricular (RV) internal end-diastolic diameter was measured in M-mode in the parasternal long-axis view /18/. RV end-diastolic thickness was measured in the subcostal view /18/. The right ventricular fractional area change (RV FAC) was measured from the apical four-chamber view. RV FAC was calculated using the formula: (end-diastolic area – end-systolic area)/end-diastolic area /18/. The right atrial (RA) transverse and longitudinal diameters were measured in the apical four-chamber view at the ventricular end-systole /18/. RA areas and volumes were obtained by using the biplane method of discs formula /18/. RA ejection fraction was calculated as (RA volume maximum - RA volume minimum)/RA volume maximum.
Tricuspid flow velocities were achieved by the standard pulsed wave Doppler technique in the apical four-chamber view. The following parameters were determined: early diastolic peak flow velocity (E_t), late diastolic flow velocity (A_t), their ratio (E/A_t) and E_t velocity deceleration time (DT_t). Tissue Doppler imaging was used to obtain the RV myocardial velocities in the apical four-chamber view with a sample volume placed at the lateral segment of the tricuspid annulus during early diastole (e´_t) and systole (s_t) /18/. (E/e´_t) ratio of the right ventricle was determined by using previously estimated Doppler values.

RV global systolic function was assessed as the tricuspid annular plane systolic excursion (TAPSE), which was measured as the difference between the distance among the tricuspid annulus and RV apex at the end-diastole and end-systole of the same cardiac cycle /18/.

The parameters necessary for the calculation of the Tei index of the right ventricle were obtained by the tissue Doppler in the apical four-chamber view according to specific guidelines /18,19/.

Assessment of the RV systolic or diastolic dysfunction, along with the global function, was based on the current recommendations /18/. RV systolic blood pressure (RVSP) was assessed in a subset of patients with minimal/mild tricuspid regurgitation.

Two-dimensional strain and strain rate

2DE strain imaging was performed by using three consecutive cardiac cycles of 2DE images in the apical four-chamber view at the end of expiration /18/. The frame rate ranged between 60 and 80 frames/s. Commercially available software EchoPAC 110.1.2, GE-Healthcare, Horten, Norway, was used for the 2DE strain analysis. The variables which were used for evaluation of systolic function and contractility were the longitudinal peak and systolic strain rate (SR), respectively. Parameters of early myocardial relaxation and late
ventricular filling were estimated by early and late diastolic strain rate. We estimated peak
longitudinal strain, systolic and diastolic strain rates for the RV and interventricular septum
separately.

The RA speckle tracking analysis was done after the endocardial border was manually
traced in the four-chamber view. Six longitudinal strain curves were generated by the
software for each atrial segment. RA peak atrial longitudinal strain was calculated by
averaging values observed in all RA segments. RA peak systolic strain rate was measured at
RV systolic phase, while early and late RA strain rates were measured during early RV filling
and throughout late RV diastolic phase, respectively.

Three-dimensional echocardiographic (3DE) acquisition

A full-volume acquisition of the RV required for further analyses was obtained by
harmonic imaging from an apical approach. Six electrocardiogram-gated consecutive beats
were acquired during end-expiratory breath-hold to generate full volume. All data sets were
stored digitally and analyzed by the commercially available software RV TomTec (EchoPAC
110.1.2, GE-Healthcare, Horten, Norway) which was used for the off-line analysis of RV
volumes, stroke volume and EF. Frame rates were between 20 and 30 frames/s.

Statistical analysis

Continuous variables were presented as mean ± standard deviation (SD) and were
compared by using the two-tailed Student’s t-test as they showed normal distribution.
Comparisons between the controls and the patients were performed by an independent-
samples t-test. The data before and after levothyroxine therapy were compared by a paired-
samples t-test. The differences in TSH levels presented as median values were analyzed using
the Mann-Whitney U test or Wilcoxon test. The differences in proportions were compared by
using the $\chi^2$ test. The correlations were determined by the Pearson rank correlation test. The p-value <0.05 was considered statistically significant.

**Results**

Basic demographic characteristics and clinical parameters of the study population are presented in Table 1. There were no differences in the prevalence of smoking, family history of coronary artery diseases or obstructive pulmonary disease between the two groups (Table 1). The controls and the SHT patients did not differ in age, BMI, BSA, heart rate or blood pressure. As it is expected FT3 and FT4 level were similar between the controls and the SHT participants (before and after substitution therapy), whereas TSH was significantly higher in the SHT patients at baseline in comparison with the controls or values after treatment (Table 1). Triglyceride level and HDL cholesterol was similar between healthy volunteers and the SHT patients. On the other hand, total cholesterol and LDL cholesterol progressively decreased from the SHT patients before therapy, amongst the SHT patients after therapy, to the controls.

*Two-dimensional echocardiographic left ventricular and atrial parameters*

Left ventricular diameters were similar between the controls and the SHT patients. Interventricular septum thickness and relative wall thickness was increased in the SHT patients at baseline in comparison with the controls (Table 2). The left atrial diameter was similar between the observed groups. The LV mass index was increased in the SHT patients at baseline in comparison with the controls and the SHT patients after therapy. LV ejection fraction was similar between the groups. Transmitial E/A ratio was significantly decreased in the SHT patients before therapy than in the controls or the SHT patients after therapy (Table 2).
Two-dimensional echocardiographic right ventricular and atrial parameters

Right ventricular and right atrial diameters, as well as RV end-systolic and end-diastolic areas were similar among the groups (Table 2). The RV thickness was increased in the SHT patients at baseline in comparison with the controls and the treated patients. The RA volumes were higher in untreated SHT participants than in the controls. The RA ejection fraction was lower in the SHT patients before therapy than in the controls or the treated SHT patients (Table 2).

Transticuspid E/A t ratio is significantly decreased, and E/e’ t ratio is significantly increased, in the SHT patients in comparison with controls and the SHT patients after therapy (Table 2). Parameters of the RV systolic function such as TAPSE and s t were similar between the observed groups. However, the Tei index, indicator of the RV global function is significantly increased in the SHT patients at baseline compared with healthy controls and the treated participants (Table 2).

Three-dimensional echocardiographic right ventricular parameters

The RV end-diastolic and stroke volumes are significantly lower in untreated SHT patients in comparison with the controls and the SHT subjects after levothyroxine therapy (Table 2). Interestingly, end-systolic RV volume was similar between the observed subjects. These hemodynamic changes result with lower 3DE RV ejection fraction among untreated SHT subjects (Table 2).

Right ventricular and atrial function – two-dimensional speckle tracking imaging

The global RV and interventricular septum longitudinal strain was decreased in the SHT subjects before the substitution therapy as opposed to the controls, but similar with treated SHT patients (Table 3). Systolic RV strain rate was decreased in untreated SHT patients in comparison with the controls and treated subjects. Early diastolic RV strain rate
was significantly increased, whereas late diastolic RV strain rate was significantly decreased, in the controls compared with the SHT patients (before and after therapy). Interventricular septum strain rates differ only between untreated SHT subjects and the controls (Table 3).

The global RA strain is decreased in the SHT patients before therapy compared with the controls (Table 3). Similar results are obtained for RA strain rates. Namely, systolic and early diastolic strain rates are increased, whereas late diastolic strain rate is decreased, in the controls compared with the SHT patients (before and after therapy). On the other hand, the difference between untreated and treated SHT patients in RA strain and strain rates is statistically insignificant.

**Correlation and regression analyses**

In the whole study population which includes the controls and the SHT patients before and after levothyroxine therapy, TSH level correlated with RV wall thickness (r=0.38, p<0.01), E/A\_t ratio (r=−0.34, p=0.01), E/e’\_t (r=0.36, p<0.01), RV Tei index (r=0.4, p<0.01), 3DE RV ejection fraction (r=−0.45, p<0.01), RV global longitudinal strain (r=−0.47, p<0.01) and RA global longitudinal strain (r=−0.42, p<0.01). However, after adjustment for LV mass index and RV wall thickness, TSH level was associated only with the RV Tei index (β=−0.32, p=0.02), 3DE RV ejection fraction (β=−0.38, p<0.01) and RV longitudinal strain (β=−0.41, p<0.01).

**Discussion**

Our study revealed several new findings: (i) RV function assessed by 3DE is deteriorated in the SHT subjects; (ii) RV mechanics evaluated by 2DE strain is significantly impaired in the SHT patients; (iii) RA mechanics is also changed in SHT; (iv) thyroxine therapy significantly improved RV and RA function and mechanics, but right heart remodeling is not completely reversible even after one year of euthyroid status.
The relationship between right heart and SHT is intriguing, and despite the fact that several studies showed an association between RV remodeling and this kind of thyroid dysfunction /9-13/, the pathophysiological explanation and mechanisms are still under debate. At the molecular level this relationship could be illuminated in several ways. First, altered management of intracellular calcium /20,21/; second, changed myocardial fiber orientation and capillary blood flow distribution /22,23/; third, reduced cardiac oxygen consumption which is associated with increased peripheral resistance, reduced contractility and decreased efficiency /24/; fourth, decreased degradation of myocardial matrix and increased insulin growth factor 1 which might induce cardiac hypertrophy and further RV dysfunction /25,26/; fifth, dyslipidemia, found also in our investigation, could have an influence on cardiac remodeling /27/; An important mechanism which should also be mentioned is increased pulmonary vascular resistance and pulmonary hypertension in SHT patients. Namely, studies showed increased prevalence of hypothyroidism in patients with pulmonary hypertension /28/, which aroused the suspicion about an autoimmune pathogenetic link between pulmonary hypertension and hypothyroidism /29/. Finally, the ventricular interaction could also be a cornerstone of RV remodeling in SHT in two ways: firstly, through the interventricular septum /30/, which transduces pressure and volume overload from the left ventricle to RV; and secondly, by transmission of increased left ventricular filling pressure through the pulmonary vascular bed to the RV.

The 2DE assessment of the RV is very challenging due to complicated RV architecture which makes it insufficiently accessible for 2DE examination. The introduction of 3DE enables the accurate quantitation of RV volumes, function and mass, and this accuracy can be compared with the results of MRI, which still remains a gold standard for the RV evaluation /31,32/. Additionally, 2DE speckle tracking imaging, unlike conventional tissue Doppler imaging, identifies RV and RA myocardial deformation during the whole
cardiac cycle, providing information not only about global strain but regional as well, and it also represents a highly reproducible imaging tool which could easily be used in everyday clinical practice /33/.

Our study showed that RV diastolic function was impaired in the SHT patients which agrees with previous investigations /9-13/. The impact of SHT on RV systolic function is more controversial. Our findings revealed that RV systolic function estimated by 3DE and 2DE speckle tracking imaging was significantly deteriorated in the SHT participants which was not found previously by using conventional echocardiographic tools /9-14/. However, Ripoli et al. using cardiac MRI showed that SHT individuals had significantly reduced cardiac preload and increased afterload with a consequent decrease in stroke volume and cardiac output /34/, which concurs with our results about the RV. Our results also could be a consequence of increased RV wall thickness among the SHT patients before levothyroxine therapy which was also found by Kosar et al. in clinical hypothyroid patients /35/.

The present study revealed that RV and RA deformation is significantly impacted by SHT which is a new finding. We would like to emphasize that RV systolic strain rate which indicates RV systolic deformation was decreased in the SHT patients at baseline in comparison with the controls and treated SHT patients; whereas RV early and late diastolic strain rates were similar between untreated and treated SHT patient, but significantly deteriorated compared with the controls. These results implicate that levothyroxine therapy improved RV systolic and diastolic function, but the improvement is not complete. In other words, RV remodeling in SHT is not completely reversible even after levothyroxine therapy and maintenance of euthyroid status for a year. Other authors showed that replacement therapy resulted with rapid and complete improvement of primarily RV diastolic function /9,10/, but we should be aware of the fact that these authors did not use techniques which could detect subtle changes in cardiac function. Our results show that RV systolic function,
estimated by 3DE RV ejection fraction, RV global systolic strain and strain rates, was
completely restored after levothyroxine therapy; whereas RV diastolic function, assessed by
RV early and late diastolic strain rates, apparently needs more time for improvement.
Interestingly, the interventricular septum does not completely follow RV changes in our SHT
patients because the difference in deformation exists only between the healthy controls and
the SHT patients at baseline, whereas its function after replacement therapy is improved and
is not significantly different from the controls. In fact, the difference is between the controls
and the SHT patients at baseline. This means that the interventricular septum and left
ventricle recover sooner than the RV which is important in determining the duration of
treatment in SHT. Furthermore, even after restoration of RV wall thickness in treated SHT
patients, RV mechanics have not been completely recovered which questions the unfavorable
influence of RV hypertrophy on RV function in SHT.

The RA function and deformation in SHT has not been evaluated before. Gaynor et al.
previously emphasized the importance of RA three-phasic function: reservoir, conduit and
booster pump function /36/. Our results revealed that systolic and diastolic RA function,
estimated by 2DE strain are significantly impaired in SHT which only contributes to the
development of RV dysfunction in these patients. The present study also showed that 2DE
RA ejection fraction was reduced in the SHT patients at baseline. Additionally, levothyroxine
therapy improved RA function and mechanics, but still not enough to reach the function of
the healthy control subjects.

Limitations

The present study has several limitations. Firstly, 3DE estimation of RV structure and
function might be significantly influenced by the quality of echocardiographic images,
especially during the full-volume acquisition. Secondly, our investigation included only
women, which restricts our results to this population. On the other hand, SHT is mostly seen in females, which is why we decided to include only women. Thirdly, the existence of coronary artery disease (CAD) was not excluded by coronary angiography, but we included young females without cardiovascular risk factors, thus expected prevalence of CAD in this population is very low.

Conclusion

The RV function and deformation assessed by 3DE and 2DE strain is significantly deteriorated in the SHT subjects. One-year levothyroxine therapy improved, but did not completely restore RV and RA myocardial function and deformation. This implies that longer substitution therapy is necessary for complete repair of the right heart in SHT patients. Prospective studies are needed to confirm the negative influence of SHT on RV remodeling, as well as to assess the effect of these impairments on morbidity and mortality in this population. Further longitudinal studies are also required to evaluate the effect of levothyroxine replacement therapy on RV remodeling and to define the duration of treatment which is needed for the complete recovery of cardiac function in SHT.

References


15. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79–108.


24. Bengel FM, Nekolla SG, Ibrahim T, Weniger C, Ziegler SI, Schwaiger M. Effect of thyroid hormones on cardiac function, geometry, and oxidative metabolism assessed
1. noninvasively by positron emission tomography and magnetic resonance imaging. J

25. Ghose Roy S, Mishra S, Ghosh G, Bandyopadhyay A. Thyroid hormone induces

7. Iervasi G. Thyroid hormone receptor and IGF1/IGFR systems: possible relations in

27. Dalen H, Thorstensen A, Romundstad PR, Aase SA, Stoylen A, Vatten LJ,
3. Cardiovascular risk factors and systolic and diastolic cardiac function: a tissue

28. Curnock AL, Dweik RA, Higgins BH, Saadi HF, Arroliga AC. High prevalence of

17. Hypothyroidism and primary pulmonary hypertension: An autoimmune pathogenetic

30. Buckberg GD, RESTORE Group. The ventricular septum: the lion of right ventricular
20. function, and its impact on right ventricular restoration. Eur J Cardiothorac Surg


32. Mor-Avi V, Lang RM. Three-dimensional echocardiographic evaluation of the heart


Table 1. Demographic characteristics and clinical parameters of study population.

<table>
<thead>
<tr>
<th></th>
<th>Controls (n=45)</th>
<th>Baseline SHT (n=50)</th>
<th>SHT after 12 months (n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>38 ± 7</td>
<td>40 ± 6</td>
<td>-</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.4 ± 4</td>
<td>24.7 ± 4.6</td>
<td>24.5 ± 4.4</td>
</tr>
<tr>
<td>BSA (m²)</td>
<td>1.71 ± 0.18</td>
<td>1.73 ± 0.15</td>
<td>1.70 ± 0.17</td>
</tr>
<tr>
<td>Smoking (%)</td>
<td>14 (31)</td>
<td>14 (28)</td>
<td>-</td>
</tr>
<tr>
<td>Positive family history of coronary artery disease (%)</td>
<td>7 (15)</td>
<td>9 (18)</td>
<td>-</td>
</tr>
<tr>
<td>Positive family history of asthma or COPD (%)</td>
<td>3 (7)</td>
<td>4 (8)</td>
<td></td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>71 ± 12</td>
<td>70 ± 11</td>
<td>72 ± 10</td>
</tr>
<tr>
<td>Clinic systolic BP (mmHg)</td>
<td>122 ± 8</td>
<td>123 ± 9</td>
<td>122 ± 9</td>
</tr>
<tr>
<td>Clinic diastolic BP (mmHg)</td>
<td>73 ± 8</td>
<td>72 ± 9</td>
<td>74 ± 7</td>
</tr>
<tr>
<td>FT3 (pmol/l)</td>
<td>2.5 ± 0.7</td>
<td>2.47 ± 0.53</td>
<td>2.6 ± 0.58</td>
</tr>
<tr>
<td>FT4 (pmol/l)</td>
<td>14.5 ± 2.5</td>
<td>14.2 ± 2.1</td>
<td>14.7 ± 2.9</td>
</tr>
<tr>
<td>TSH (mIU/ml)</td>
<td>2.23 ± 0.8b</td>
<td>8.23 ± 2.11b,f</td>
<td>2.07 ± 0.75f</td>
</tr>
<tr>
<td>TSH [median (range)] (mIU/ml)</td>
<td>2.1 (0.8-3.8)b</td>
<td>8.1 (5.1-11)b,f</td>
<td>2 (0.7-3.4)f</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.21 ± 0.68</td>
<td>1.33 ± 0.66</td>
<td>1.28 ± 0.65</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>4.58 ± 0.74b,d</td>
<td>5.44± 0.92b,e</td>
<td>5.09 ± 0.8d,e</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/l)</td>
<td>2.6 ± 0.59b,d</td>
<td>3.3 ± 0.7b,e</td>
<td>3 ± 0.63d,e</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/l)</td>
<td>1.52 ± 0.27</td>
<td>1.44 ± 0.24</td>
<td>1.47 ± 0.25</td>
</tr>
</tbody>
</table>

BMI - body mass index, BSA - body surface area, BP - blood pressure, COPD - chronic pulmonary disease, FT3 - free triiodothyronine, FT4 - free thyroxine, TSH - thyroid-stimulated hormone, STA - subclinical hypothyroidism

b- p<0.01 for Controls vs. Baseline, d- p<0.01 for Controls vs. SHT after 12 months, e- p<0.05 for Baseline vs. SHT after 12 months, f- p<0.01 for Baseline vs. SHT after 12 months
Table 2. Echocardiographic parameters of left and right ventricular structure and function in the study population.

<table>
<thead>
<tr>
<th></th>
<th>Controls (n=45)</th>
<th>Baseline SHT (n=50)</th>
<th>SHT after 12 months (n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2D left ventricular and atrial parameters</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVEDD (mm)</td>
<td>45.2 ± 4.4</td>
<td>46.1 ± 4.7</td>
<td>45.5 ± 4.6</td>
</tr>
<tr>
<td>LVESD (mm)</td>
<td>31.1 ± 3.6</td>
<td>32 ± 4.3</td>
<td>32.1 ± 4.2</td>
</tr>
<tr>
<td>IVS (mm)</td>
<td>8.9 ± 1.1b</td>
<td>9.4 ± 1.2b</td>
<td>9.1 ± 1.1</td>
</tr>
<tr>
<td>RWT</td>
<td>0.37 ± 0.04b</td>
<td>0.39 ± 0.03b</td>
<td>0.38 ± 0.03</td>
</tr>
<tr>
<td>LA (mm)</td>
<td>35 ± 3.4</td>
<td>35.8 ± 3.7</td>
<td>35.5 ± 3.6</td>
</tr>
<tr>
<td>LVM/HT² (g/m².7)</td>
<td>39.8 ± 4.7b</td>
<td>44.3 ± 5.1b,f</td>
<td>40.8 ± 4.9f</td>
</tr>
<tr>
<td>EF (%)</td>
<td>64 ± 4</td>
<td>63 ± 5</td>
<td>64 ± 5</td>
</tr>
<tr>
<td>(E/A)₀ ratio</td>
<td>1.48 ± 0.35b</td>
<td>1.19 ± 0.39b,f</td>
<td>1.39 ± 0.33f</td>
</tr>
<tr>
<td><strong>2D right ventricular and atrial parameters</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RVDDd outflow (mm)</td>
<td>23.5 ± 2.4</td>
<td>24.2 ± 2.7</td>
<td>23.8 ± 2.5</td>
</tr>
<tr>
<td>RVTd subcostal (mm)</td>
<td>3.9 ± 0.6a</td>
<td>4.2 ± 0.8a,e</td>
<td>3.8 ± 0.7e</td>
</tr>
<tr>
<td>RV EDA (cm²)</td>
<td>15 ± 3.4</td>
<td>15.5 ± 3.8</td>
<td>15.2 ± 3.5</td>
</tr>
<tr>
<td>RV ESA (cm²)</td>
<td>7.3 ± 3</td>
<td>7.8 ± 3.5</td>
<td>7.5 ± 3.1</td>
</tr>
<tr>
<td>RV FAC (%)</td>
<td>51 ± 5</td>
<td>50 ± 4</td>
<td>51 ± 4</td>
</tr>
<tr>
<td>RA long axis (mm)</td>
<td>37.9 ± 6.5</td>
<td>38.8 ± 6.9</td>
<td>38.2 ± 6.6</td>
</tr>
<tr>
<td>RA short axis (mm)</td>
<td>30.7 ± 4.5</td>
<td>31.4 ± 4.7</td>
<td>31.4 ± 1.1</td>
</tr>
<tr>
<td>RA volume max (ml)</td>
<td>37 ± 7</td>
<td>40 ± 8</td>
<td>38 ± 6</td>
</tr>
<tr>
<td>RA volume min (ml)</td>
<td>14 ± 4</td>
<td>16 ± 5a</td>
<td>15 ± 5</td>
</tr>
<tr>
<td>RA EF (%)</td>
<td>63 ± 4b,4c</td>
<td>59 ± 3b,4e</td>
<td>61 ± 5b,e</td>
</tr>
<tr>
<td>E/A₁</td>
<td>1.45 ± 0.34b</td>
<td>1.18 ± 0.27b,f</td>
<td>1.38 ± 0.3f</td>
</tr>
<tr>
<td>E/e´₁</td>
<td>4.15 ± 1.04a</td>
<td>4.76 ± 1.26a,e</td>
<td>4.27 ± 1.11f</td>
</tr>
<tr>
<td>s₁ (cm/s)</td>
<td>14 ± 2.3</td>
<td>13.6 ± 2.4</td>
<td>13.8 ± 2.5</td>
</tr>
<tr>
<td>TAPSE (mm)</td>
<td>24 ± 4</td>
<td>23 ± 3</td>
<td>24 ± 3</td>
</tr>
<tr>
<td>SPAP (mmHg)</td>
<td>18 ± 5</td>
<td>20 ± 4</td>
<td>19 ± 4</td>
</tr>
<tr>
<td>RV Tei index</td>
<td>0.42 ± 0.05b,c</td>
<td>0.5 ± 0.07b,f</td>
<td>0.45 ± 0.06c,f</td>
</tr>
<tr>
<td><strong>3D right ventricular parameters</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RV EDV (ml)</td>
<td>121 ± 19b</td>
<td>106 ± 16b,e</td>
<td>116 ± 20e</td>
</tr>
<tr>
<td>RV ESV (ml)</td>
<td>47 ± 7</td>
<td>45 ± 6</td>
<td>46 ± 6</td>
</tr>
<tr>
<td>RV SV (ml)</td>
<td>74 ± 8b,c</td>
<td>61 ± 6b,f</td>
<td>70 ± 7c,f</td>
</tr>
<tr>
<td>RV EF₃D (%)</td>
<td>61 ± 5b</td>
<td>58 ± 4b,4,e</td>
<td>60 ± 5c</td>
</tr>
</tbody>
</table>

A- late diastolic mitral/tricuspid flow (pulse Doppler), BSA – body surface area, DT-deceleration time, E- early diastolic mitral/tricuspid flow (pulse Doppler), e´- peak early diastolic relaxation velocity of the lateral segment of tricuspid annulus (tissue Doppler), EDA- end-diastolic area, EDV- end-diastolic volume, EF-ejection fraction, ESA-end-systolic area, ESV-end-systolic volume, FAC-fractional area change, HT-height, IVS-interventricular septum, LA-left atrium, LV-left ventricle, LVM-left ventricular mass, RA-right atrium, RV-right ventricle, RVD-right ventricular diameter, RVT-right ventricular wall thickness, RWT-relative wall thickness, SPAP-systolic pressure in pulmonary artery, SV-stroke volume.

a- p<0.05 for Controls vs. Baseline SHT, b- p<0.01 for Controls vs. Baseline, c- p<0.05 for Controls vs. SHT after 12 months, e- p<0.05 for Baseline vs. SHT after 12 months, f- p<0.01 for Baseline vs. SHT after 12 months.
Table 3. Echocardiographic parameters of right ventricular function (2D strain) in the study population.

<table>
<thead>
<tr>
<th></th>
<th>Controls (n=45)</th>
<th>Baseline SHT (n=50)</th>
<th>SHT after 12 months (n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2DE RV strain and strain rates</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Longitudinal RV strain (%)</td>
<td>- 29 ± 6&lt;sup&gt;b&lt;/sup&gt;</td>
<td>- 26 ± 5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>- 28 ± 5</td>
</tr>
<tr>
<td>Septum</td>
<td>- 24 ± 5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>- 22 ± 4&lt;sup&gt;a&lt;/sup&gt;</td>
<td>- 23 ± 4</td>
</tr>
<tr>
<td>RV systolic strain rate (s&lt;sup&gt;-1&lt;/sup&gt;)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global RV</td>
<td>- 1.83 ± 0.44&lt;sup&gt;b&lt;/sup&gt;</td>
<td>- 1.52 ± 0.41&lt;sup&gt;b,e&lt;/sup&gt;</td>
<td>- 1.69 ± 0.42&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
<tr>
<td>Septum</td>
<td>- 1.65 ± 0.4&lt;sup&gt;b&lt;/sup&gt;</td>
<td>- 1.4 ± 0.31&lt;sup&gt;b&lt;/sup&gt;</td>
<td>- 1.53 ± 0.38</td>
</tr>
<tr>
<td>RV early diastolic strain rate (s&lt;sup&gt;-1&lt;/sup&gt;)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global RV</td>
<td>1.9 ± 0.41&lt;sup&gt;b,c&lt;/sup&gt;</td>
<td>1.6 ± 0.45&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.72 ± 0.42&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Septum</td>
<td>1.76 ± 0.36&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.5 ± 0.4&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.64 ± 0.38</td>
</tr>
<tr>
<td>RV late diastolic strain rate (s&lt;sup&gt;-1&lt;/sup&gt;)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global RV</td>
<td>1.46 ± 0.33&lt;sup&gt;b,c&lt;/sup&gt;</td>
<td>1.72 ± 0.36&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.6 ± 0.42&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Septum</td>
<td>1.41 ± 0.3&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.64 ± 0.35&lt;sup&gt;b&lt;/sup&gt;</td>
<td>1.52 ± 0.33</td>
</tr>
<tr>
<td><strong>2DE RA strain and strain rate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Longitudinal RA strain (%)</td>
<td>46 ± 7&lt;sup&gt;b&lt;/sup&gt;</td>
<td>42 ± 6&lt;sup&gt;b&lt;/sup&gt;</td>
<td>44 ± 6</td>
</tr>
<tr>
<td>RA systolic strain rate (s&lt;sup&gt;-1&lt;/sup&gt;)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.2 ± 0.6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.95 ± 0.56&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.08 ± 0.62</td>
<td></td>
</tr>
<tr>
<td>RA early diastolic strain rate (s&lt;sup&gt;-1&lt;/sup&gt;)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- 2.43 ± 0.72&lt;sup&gt;a&lt;/sup&gt;</td>
<td>- 2.12 ± 0.65&lt;sup&gt;a&lt;/sup&gt;</td>
<td>- 2.3 ± 0.66</td>
<td></td>
</tr>
<tr>
<td>RA late diastolic strain rate (s&lt;sup&gt;-1&lt;/sup&gt;)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- 2 ± 0.6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>- 2.28 ± 0.67&lt;sup&gt;a&lt;/sup&gt;</td>
<td>- 2.08 ± 0.62</td>
<td></td>
</tr>
</tbody>
</table>

RA- right atrium, RV-right ventricle.

a-p<0.05 for Controls vs. Baseline SHT, b- p<0.01 for Controls vs. Baseline, c- p<0.05 for Controls vs. SHT after 12 months, e-p<0.05 for Baseline vs. SHT after 12 months